Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11884288rdf:typepubmed:Citationlld:pubmed
pubmed-article:11884288lifeskim:mentionsumls-concept:C0026809lld:lifeskim
pubmed-article:11884288lifeskim:mentionsumls-concept:C0026473lld:lifeskim
pubmed-article:11884288lifeskim:mentionsumls-concept:C0016390lld:lifeskim
pubmed-article:11884288lifeskim:mentionsumls-concept:C0064847lld:lifeskim
pubmed-article:11884288lifeskim:mentionsumls-concept:C1334350lld:lifeskim
pubmed-article:11884288lifeskim:mentionsumls-concept:C0392756lld:lifeskim
pubmed-article:11884288lifeskim:mentionsumls-concept:C0680242lld:lifeskim
pubmed-article:11884288pubmed:issue3lld:pubmed
pubmed-article:11884288pubmed:dateCreated2002-3-8lld:pubmed
pubmed-article:11884288pubmed:abstractTextLeukotriene B4 (LTB4) is a potent chemotactic agent that activates monocytes through the LTB4 receptor (BLTR). We tested the hypothesis that LTB4 receptor blockade would slow atherosclerotic progression by inhibiting monocyte recruitment. Homozygous low-density receptor knockout (LDLr(-/-)) mice and apolipoprotein E deficient (apoE(-/-)) mice were treated with a specific LTB4 receptor antagonist, CP-105,696, for 35 days. In apoE(-/-)mice, treatment with the LTB4 antagonist did not affect plasma lipid concentrations but significantly reduced CD11b levels both in vascular lesions and whole blood. Compared with age-matched controls, lipid accumulation and monocyte infiltration were significantly reduced in treated apoE(-/-) mice at all time points tested. Lesion area reduction was also demonstrated in LDLr(-/-) mice maintained on a high-fat diet. LTB4 antagonism had no significant effect on lesion size in mice possessing the null alleles for another chemotactic agent, monocyte chemoattractant protein-1 (MCP-1(-/-)xapoE(-/-)), suggesting MCP-1 and LTB4 may either interact or exert their effects by a common mechanism. These results demonstrate that in a preclinical model of atherosclerosis LTB4 receptor blockade reduces lesion progression and further suggest a previously unrecognized role for LTB4 or other oxidized lipids recognized by the BLTR receptor in the pathogenesis of this disease.lld:pubmed
pubmed-article:11884288pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11884288pubmed:languageenglld:pubmed
pubmed-article:11884288pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11884288pubmed:citationSubsetIMlld:pubmed
pubmed-article:11884288pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11884288pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11884288pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11884288pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11884288pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11884288pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11884288pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11884288pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11884288pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11884288pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11884288pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11884288pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11884288pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11884288pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11884288pubmed:statusMEDLINElld:pubmed
pubmed-article:11884288pubmed:monthMarlld:pubmed
pubmed-article:11884288pubmed:issn1524-4636lld:pubmed
pubmed-article:11884288pubmed:authorpubmed-author:AielloRobert...lld:pubmed
pubmed-article:11884288pubmed:authorpubmed-author:BourassaPatri...lld:pubmed
pubmed-article:11884288pubmed:authorpubmed-author:LindseySaraly...lld:pubmed
pubmed-article:11884288pubmed:authorpubmed-author:WengWeifanWlld:pubmed
pubmed-article:11884288pubmed:authorpubmed-author:FreemanAnnAlld:pubmed
pubmed-article:11884288pubmed:authorpubmed-author:ShowellHenry...lld:pubmed
pubmed-article:11884288pubmed:issnTypeElectroniclld:pubmed
pubmed-article:11884288pubmed:day1lld:pubmed
pubmed-article:11884288pubmed:volume22lld:pubmed
pubmed-article:11884288pubmed:ownerNLMlld:pubmed
pubmed-article:11884288pubmed:authorsCompleteYlld:pubmed
pubmed-article:11884288pubmed:pagination443-9lld:pubmed
pubmed-article:11884288pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:11884288pubmed:meshHeadingpubmed-meshheading:11884288...lld:pubmed
pubmed-article:11884288pubmed:meshHeadingpubmed-meshheading:11884288...lld:pubmed
pubmed-article:11884288pubmed:meshHeadingpubmed-meshheading:11884288...lld:pubmed
pubmed-article:11884288pubmed:meshHeadingpubmed-meshheading:11884288...lld:pubmed
pubmed-article:11884288pubmed:meshHeadingpubmed-meshheading:11884288...lld:pubmed
pubmed-article:11884288pubmed:meshHeadingpubmed-meshheading:11884288...lld:pubmed
pubmed-article:11884288pubmed:meshHeadingpubmed-meshheading:11884288...lld:pubmed
pubmed-article:11884288pubmed:meshHeadingpubmed-meshheading:11884288...lld:pubmed
pubmed-article:11884288pubmed:meshHeadingpubmed-meshheading:11884288...lld:pubmed
pubmed-article:11884288pubmed:meshHeadingpubmed-meshheading:11884288...lld:pubmed
pubmed-article:11884288pubmed:meshHeadingpubmed-meshheading:11884288...lld:pubmed
pubmed-article:11884288pubmed:meshHeadingpubmed-meshheading:11884288...lld:pubmed
pubmed-article:11884288pubmed:meshHeadingpubmed-meshheading:11884288...lld:pubmed
pubmed-article:11884288pubmed:meshHeadingpubmed-meshheading:11884288...lld:pubmed
pubmed-article:11884288pubmed:meshHeadingpubmed-meshheading:11884288...lld:pubmed
pubmed-article:11884288pubmed:meshHeadingpubmed-meshheading:11884288...lld:pubmed
pubmed-article:11884288pubmed:meshHeadingpubmed-meshheading:11884288...lld:pubmed
pubmed-article:11884288pubmed:meshHeadingpubmed-meshheading:11884288...lld:pubmed
pubmed-article:11884288pubmed:meshHeadingpubmed-meshheading:11884288...lld:pubmed
pubmed-article:11884288pubmed:meshHeadingpubmed-meshheading:11884288...lld:pubmed
pubmed-article:11884288pubmed:meshHeadingpubmed-meshheading:11884288...lld:pubmed
pubmed-article:11884288pubmed:year2002lld:pubmed
pubmed-article:11884288pubmed:articleTitleLeukotriene B4 receptor antagonism reduces monocytic foam cells in mice.lld:pubmed
pubmed-article:11884288pubmed:affiliationDepartment of Cardiovascular and Metabolic Disease, Pfizer Global Research and Development, Groton, Conn 06340, USA. robert_j_aiello@groton.pfizer.com.lld:pubmed
pubmed-article:11884288pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11884288lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11884288lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11884288lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11884288lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11884288lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11884288lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11884288lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11884288lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11884288lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11884288lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11884288lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11884288lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11884288lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11884288lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11884288lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11884288lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11884288lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11884288lld:pubmed